Double-blind, placebo-controlled, randomized investigation of Ondansetron in chronic residual schizophrenia

Project: Research

StatusFinished
Effective start/end date21/01/1020/01/13

Funding

  • The Stanley Medical Research Institute: AUD99,814.80
  • The Stanley Medical Research Institute: AUD898,590.35